Affymetrix, Inc.  

(Public, NASDAQ:AFFX)   Watch this stock  
Find more results for AFFX
6.90
+0.09 (1.32%)
Real-time:   12:42PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.71 - 6.91
52 week 3.22 - 9.80
Open 6.89
Vol / Avg. 394,666.00/1.10M
Mkt cap 500.12M
P/E     -
Div/yield     -
EPS -0.23
Shares 72.48M
Beta 1.27
Inst. own 125%
May 1, 2014
Q1 2014 Affymetrix Earnings Conference Call - 5:00PM EDT - Add to calendar
May 1, 2014
Q1 2014 Affymetrix Earnings Release - 4:00PM EDT - Add to calendar
Feb 5, 2014
Q4 2013 Affymetrix Earnings Conference Call - Webcast
Feb 5, 2014
Q4 2013 Affymetrix Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 10.12% -4.94%
Operating margin 4.20% -3.80%
EBITD margin - 9.36%
Return on average assets 7.41% -3.11%
Return on average equity 14.21% -5.95%
Employees 1,100 -
CDP Score - -

Address

3420 Central Expressway
SANTA CLARA, CA 95051
United States - Map
+1-408-7315000 (Phone)
+1-408-7315380 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Affymetrix, Inc. (Affymetrix) is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets. Affymetrix has developed its GeneChip system and related microarray technology as a platform for acquiring, analyzing and managing genetic information. The Company offers a line of products for two principal applications: genotyping and gene expression. Related microarray technology also offered by Affymetrix includes licenses for fabricating, scanning, collecting and analyzing results from complementary technologies. The Company also sells some of its products through life science supply specialists acting as authorized distributors in Latin America, India, the Middle East and Asia Pacific regions, including China. In October 2013, StoneCalibre announced that the completion of the acquisition of Anatrace, a part of Affymetrix, Inc.

Officers and directors

Stephen P. A. Fodor Ph.D. Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Frank R. Witney Ph.D. President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Gavin Wood Chief Financial Officer, Executive Vice President
Age: 43
Bio & Compensation  - Reuters
Andrew J. Last Ph.D. Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Siang Chin General Counsel, Secretary
Bio & Compensation  - Reuters
David Weber Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Robert P. Wayman Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Nelson C. Chan Independent Director
Age: 52
Bio & Compensation  - Reuters
Gary S. Guthart Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Jami Dover Nachtsheim Independent Director
Age: 54
Bio & Compensation  - Reuters